Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.46 |
| ▸ | PGK2 | P07205 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 2/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919300 | 0.81 | CCNT1 (0.39) | HMGCRPDE3BPDE3APPARGPPARA | |
| SCHEMBL5660361 | 0.79 | PGK1 (0.52) | PGK1PGK2PTPRBCYP3A4KMT2A | |
| SCHEMBL8199992 | 0.79 | PTGS2 (0.53) | PGK1PGK2PTPRBCYP3A4MEN1 | |
| SCHEMBL918362 | 0.77 | HMGCR (0.44) | HMGCRPDE3BPDE3APPARGPPARA | |
| SCHEMBL918847 | 0.76 | PTGS2 (0.59) | HMGCRPDE3BPDE3AALDH1A1CYP3A4 | |
| SCHEMBL6935944 | 0.76 | CYP1A2 (0.41) | HMGCRPDE3BPDE3APPARGPPARA | |
| SCHEMBL4576123 | 0.75 | GSTA1 (0.39) | HMGCRPDE3BPDE3ARAB9AMEN1 | |
| SCHEMBL3815603 | 0.75 | PGK1 (0.47) | PGK1PGK2PTPRBALDH1A1THRA | |
| SCHEMBL919348 | 0.74 | PTGS2 (0.42) | HMGCRPDE3BPDE3AALDH1A1CYP3A4 | |
| SCHEMBL2984364 | 0.74 | CA2 (0.57) | PPARGPPARAALDH1A1CYP3A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| EP-1554236-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | Welichem Biotech Inc. (CA) | 2005-07-20 | — | — | EP | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2004031117-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | WELICHEM BIOTECH INC. (CA) | 2004-04-15 | — | — | WO | disclosed |
| EP-1368306-A1 | NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES | Welichem Biotech Inc. (CA) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002057219-A1 | NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES | WELICHEM BIOTECH INC. (CA) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | PGK1 73/4885PGK2 83/4885ENPP2 94/4885 |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | PGK1 809/4885PGK2 980/4885ENPP2 505/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | PGK1 258/4885PGK2 297/4885ENPP2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.